Company Filing History:
Years Active: 2018
Title: Tim Illidge: Innovator in Cancer Treatment
Introduction
Tim Illidge is a notable inventor based in Manchester, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on enhancing the efficacy of radiation therapy in combination with specific antagonists.
Latest Patents
Tim Illidge holds a patent titled "Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy." This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist. Notably, at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including four days later. He has 1 patent to his name.
Career Highlights
Tim Illidge is associated with Medimmune Limited, where he continues to push the boundaries of cancer treatment. His work is characterized by a commitment to improving patient outcomes through innovative therapeutic strategies.
Collaborations
Tim collaborates with esteemed colleagues, including Ross Anthony Stewart and Michelle Morrow. Their combined expertise contributes to the advancement of cancer treatment methodologies.
Conclusion
Tim Illidge's contributions to cancer treatment through his innovative patent demonstrate his dedication to improving healthcare outcomes. His work continues to inspire advancements in the field of oncology.